TY - JOUR T1 - Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry JF - RMD Open JO - RMD Open DO - 10.1136/rmdopen-2022-002508 VL - 8 IS - 2 SP - e002508 AU - Su-Ann Yeoh AU - Milena Gianfrancesco AU - Saskia Lawson-Tovey AU - Kimme L Hyrich AU - Anja Strangfeld AU - Laure Gossec AU - Loreto Carmona AU - Elsa F Mateus AU - Martin Schäfer AU - Christophe Richez AU - Eric Hachulla AU - Marie Holmqvist AU - Carlo Alberto Scirè AU - Hanns-Martin Lorenz AU - Reinhard E Voll AU - Rebecca Hasseli AU - Arundathi Jayatilleke AU - Tiffany Y-T Hsu AU - Kristin M D’Silva AU - Victor R Pimentel-Quiroz AU - Monica Vasquez del Mercado AU - Samuel Katsuyuki Shinjo AU - Edgard Torres dos Reis Neto AU - Laurindo Ferreira da Rocha Junior AU - Ana Carolina de Oliveira e Silva Montandon AU - Guillermo J Pons-Estel AU - Sofía Ornella AU - Maria Eugenia D'Angelo Exeni AU - Edson Velozo AU - Paula Jordan AU - Emily Sirotich AU - Jonathan S Hausmann AU - Jean W Liew AU - Lindsay Jacobsohn AU - Monique Gore-Massy AU - Paul Sufka AU - Rebecca Grainger AU - Suleman Bhana AU - Zachary Wallace AU - Philip C Robinson AU - Jinoos Yazdany AU - Pedro M Machado A2 - , Y1 - 2022/09/01 UR - http://rmdopen.bmj.com/content/8/2/e002508.abstract N2 - Objectives To investigate factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy (IIM).Methods Demographic data, clinical characteristics and COVID-19 outcome severity of adults with IIM were obtained from the COVID-19 Global Rheumatology Alliance physician-reported registry. A 3-point ordinal COVID-19 severity scale was defined: (1) no hospitalisation, (2) hospitalisation (and no death) and (3) death. ORs were estimated using multivariable ordinal logistic regression. Sensitivity analyses were performed using a 4-point ordinal scale: (1) no hospitalisation, (2) hospitalisation with no oxygen (and no death), (3) hospitalisation with oxygen/ventilation (and no death) and 4) death.Results Of 348 patients, 48% were not hospitalised, 39% were hospitalised (and did not die) and 13% died. Older age (OR=1.59/decade, 95% CI 1.31 to 1.91), high disease activity (OR=3.50, 95% CI 1.25 to 9.83; vs remission), ≥2 comorbidities (OR=2.63, 95% CI 1.39 to 4.98; vs none), prednisolone-equivalent dose >7.5 mg/day (OR=2.40, 95% CI 1.09 to 5.28; vs no intake) and exposure to rituximab (OR=2.71, 95% CI 1.28 to 5.72; vs conventional synthetic disease-modifying antirheumatic drugs only) were independently associated with severe COVID-19. In addition to these variables, in the sensitivity analyses, male sex (OR range: 1.65–1.83; vs female) was also significantly associated with severe outcomes, while COVID-19 diagnosis after 1 October 2020 (OR range: 0.51–0.59; vs on/before 15 June 2020) was significantly associated with less severe outcomes, but these associations were not significant in the main model (OR=1.57, 95% CI 0.95 to 2.59; and OR=0.61, 95% CI 0.37 to 1.00; respectively).Conclusions This is the first large registry data on outcomes of COVID-19 in people with IIM. Older age, male sex, higher comorbidity burden, high disease activity, prednisolone-equivalent dose >7.5 mg/day and rituximab exposure were associated with severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with IIM.Data are available on reasonable request. Applications to access the data should be made to the COVID-19 Global Rheumatology Alliance Steering Committee. ER -